The Key Players Global Acute Lymphocytic Leukemia Market 2015-2019, According to a New Study on ASDReports

Monday 16 November 2015, Amsterdam

Market Research Report Press Release The report, now available on ASDReports, recognizes the following companies as the key players in the Global Acute Lymphocytic Leukemia Market: Amgen, Bristol-Myers Squibb and Novartis

Other Prominent Vendors in the market are: Ariad, Arno Therapeutics, Baxter, Boehringer Ingelheim, ERYTECH Pharma, Fate Therapeutics, Jazz Pharmaceuticals, Orphan Europe, Otsuka, Ono Pharmaceuticals, Onconova Therapeutics, Pfizer, Regeneron Pharmaceuticals, Sanofi, and Sigma-Tau Pharmaceuticals.

Commenting on the report, an analyst said: “The rise in awareness programs to treat acute lymphocytic leukemia patients is one such trend. It increases the treatment-seeking rate among patients, which results in an increase in overall consumption of medicines.”

According to the report, the global acute lymphocytic leukemia therapeutics market is driven by several factors. The presence of high unmet needs for appropriate drugs is one of the major factors propelling the growth of the market. Current treatment options cannot cure the disease completely, hence the demand remains high. Therefore, drugs that can cause disease remission in patients are expected to drive the growth of the market.

Further, the report states that the high cost of treatment is one of the major challenges hindering the growth of the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Global Acute Lymphocytic/Lymphoblastic leukemia Market 2015-2019

Global Acute Lymphocytic/Lymphoblastic leukemia Market 2015-2019

Publish date : November 2015
Report code : ASDR-228790
Pages : 65

ASDReports.com Media contact: S. Koopman - Marketing and Communications

ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : stefan.koopman@asdreports.com

 back to News